Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00139906 · ClinicalTrials.gov registry record · Phase 2
Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia
A Phase 2 study, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00139906 is a Phase 2 study that has completed, run by Solvay Pharmaceuticals.
The verdict
NCT00139906, a Phase 2 study, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.
Interventions
- DRUG Bifeprunox
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-08 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00139906
The ClinicalTrials.gov registry entry for NCT00139906 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Solvay Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bifeprunox is the first listed.
NCT00139906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00139906 about?
NCT00139906 is a clinical study titled "Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia". This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months.
What is the current status of trial NCT00139906?
This trial is currently completed. It is a Phase 2 study. The study started on 2005-08. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00139906?
The interventions under investigation include: Bifeprunox (DRUG).
Who is sponsoring clinical trial NCT00139906?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.